PMC members shape and advance the future of personalized medicine.
» Sign Up Today
Echoing contentions made by PMC in its most recent white paper, Paying for Personalized Medicine, Barbara L. McAneny, M.D., the immediate past chair of the American Medical Association (AMA) Board of Trustees, has voiced her support for ensuring that future advancements in personalized medicine are considered early in the development of alternative payment models (APMs) that include clinical pathways.
» Inside Health Policy (subscription content)
» Evidence-Based Oncology
CMS Recognizes Value of New Personalized Therapy
Pharmaceutical companies developing personalized medicines still face profound challenges in reimbursement, but a recent decision from Medicare offers new hope that the agency is willing to begin addressing those challenges.
» The New York Times
Senate Likely to Wait Until 2016 to Act on Medical Innovation
Senate Health, Education, Labor & Pensions (HELP) Committee Chairman Sen. Lamar Alexander (R-TN) has indicated that the chamber will likely wait until next year to pass a medical bill that could serve as a counterpart to the House's 21st Century Cures Act.
» CQ Roll Call (subscription content)
Adding to the number of proposals for the regulation of laboratory-developed tests (LDTs), many of which help identify appropriate candidates for personalized medicines, the Association for Molecular Pathology (AMP) has presented the relevant committee in the Senate with a proposal to strengthen the Clinical Laboratory Improvement Amendments (CLIA).
» AMP press release
Dohmen CEO Wins PharmaVOICE 100 Award
Dohmen Life Science Services CEO Cynthia LaConte is using her company to connect innovators directly with the patients they serve. She has received PharmaVOICE magazine's PharmaVOICE 100 Award for her efforts.
» Dohmen Life Science Services press release
Wall Street Journal
Cancer Specialist Criticizes High Prices for New Drugs
Wall Street Journal
U.S. Cancer Study to Match Existing Drugs to Genetic Mutations